• Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S7111 NLG919 <1 mg/mL 15 mg/mL 30 mg/mL
S7756 Indoximod (NLG-8189) <1 mg/mL 1 mg/mL <1 mg/mL
S7910 Epacadostat (INCB024360) <1 mg/mL 87 mg/mL 53 mg/mL
S7587 INCB024360 analogue <1 mg/mL 54 mg/mL 54 mg/mL
S8629 BMS-986205 <1 mg/mL 82 mg/mL 82 mg/mL
S8657 PF-06840003 <1 mg/mL 46 mg/mL 6 mg/mL
Catalog No. Information Product Use Citations Product Validations


NLG919 is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM in cell-free assays. Phase 1.


Indoximod (NLG-8189)

Indoximod (NLG-8189), a methylated tryptophan, acts as an IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, and reverses IDO-mediated immune suppression. Phase 2.


Epacadostat (INCB024360)

Epacadostat (INCB024360) is a potent and selective indoleamine 2,3-dioxygenase (IDO1) inhibitor with IC50 of 10 nM and displays high selectivity over other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO).


IDO inhibitor 1

IDO inhibitor 1 is a potent inhibitor of IDO (indoleamine-(2,3)-dioxygenase) with IC50 of 3 nM.


INCB024360 analogue

INCB024360 analogue is a potent, competitive IDO1 (indoleamine-(2,3)-dioxygenase) inhibitor with IC50 of 67 nM. Phase 2.



BMS-986205 is an irreversible inhibitor of IDO1 with an IC50 of 1.7 nM. It inhibits kynurenine production with IC50 values of 1.7, 1.1 and > 2000 in human HeLa, HEK293 expressing human IDO-1 and tryptophan-2, 3-dioxygenase cell-based assays.



PF-06840003 is a highly selective orally bioavailable IDO-1 inhibitor. Although it has moderate hIDO1 enzyme inhibition (IC50 0.41 μM), it is a highly efficient compound (LE 0.53, LipE 5.1), driven by its tight packing within the enzyme, as well as the high density of hydrogen bonds it forms with hIDO-1 despite its small size.